A Multicenter, Randomized, Open-label, Active-controlled, Dose-range Finding Study to Assess the Pharmacodynamic Parameters, Safety and Tolerability of MAA868 and Its Effect on Thrombogenesis Biomarkers Compared to Apixaban in Patients With Atrial Fibrillation
Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 10 Oct 2018
At a glance
- Drugs MAA 868 (Primary) ; Apixaban
- Indications Atrial fibrillation
- Focus Therapeutic Use
- Sponsors Novartis Pharma A.G.; Novartis Pharmaceuticals
- 03 Oct 2018 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 28 Sep 2018 Status changed from withdrawn prior to enrolment to not yet recruiting.
- 10 Sep 2018 Status changed from not yet recruiting to withdrawn prior to enrolment.